SEATTLE--(BUSINESS WIRE)--Oct. 23, 2017--
Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy
company focused on developing treatments for autoimmune diseases and
cancer, today announced it has extended the research term of its
worldwide research and license agreement with Kite, a Gilead
The research collaboration and license agreement, initiated in October
2015, grants Kite an exclusive license to two Alpine programs from
Alpine’s Transmembrane Immunomodulatory Protein (TIP) program. The
license allows Kite to further engineer these candidates into chimeric
antigen receptor (CAR-T) and T cell receptor (TCR) product candidates.
The research term extension does not change the $535 million in up front
and potential regulatory milestones payable to Alpine in the original
agreement or royalties Alpine may earn on potential future sales of Kite
products incorporating Alpine’s TIP technology. Kite will continue to
have access to two programs from Alpine’s TIP technology for use in
CAR-T and TCRs during the extended research term.
About Alpine Immune Sciences, Inc.Alpine Immune Sciences, Inc.
is focused on developing novel protein-based immunotherapies using its
proprietary Variant Ig Domain (vIgD) platform technology. The vIgD
platform is designed to interact with multiple targets, including many
present in the immune synapse. Alpine’s vIgDs are developed using a
process known as directed evolution, which produces proteins capable of
either enhancing or diminishing an immune response and thereby may
potentially apply therapeutically to cancer, autoimmune, and
inflammatory diseases. Alpine has also developed TIP technology, based
on the vIgD platform, to potentially enhance engineered cellular
therapies. For more information visit www.alpineimmunesciences.com/.
This release contains forward-looking statements within the meaning
of Section 27A of the Securities Act of 1933, Section 21E of the
Securities Exchange Act of 1934 and the Private Securities Litigation
Reform Act of 1995. These forward-looking statements are not based on
historical fact and include statements regarding Alpine’s platform
technology, potential therapies, potential milestone and royalty
payments, future development plans, and clinical and regulatory
objectives. Forward-looking statements generally include statements that
are predictive in nature and depend upon or refer to future events or
conditions, and include words such as “may,” “will,” “should,” “would,”
“expect,” “plan,” “intend,” and other similar expressions among others.
These forward-looking statements are based on current assumptions
involving risks, uncertainties, and other factors that may cause actual
results, events, or developments to be materially different from those
expressed or implied by such forward-looking statements. These risks and
uncertainties, many of which are beyond our control, include, but are
not limited to: Alpine’s discovery-stage and pre-clinical programs may
not advance into the clinic or result in approved products on a timely
or cost-effective basis or at all; Alpine may not achieve additional
milestone payments pursuant to its collaborations; the impact of
competition; adverse conditions in the general domestic and global
economic markets; as well as the other risks identified in our filings
with the Securities and Exchange Commission. These forward-looking
statements speak only as of the date hereof, Alpine undertakes no
obligation to update forward-looking statements, and readers are
cautioned not to place undue reliance on such forward-looking statements.
“Transmembrane Immunomodulatory Protein,” “TIP,” “Variant Ig Domain,”
“vIgD,” and the Alpine logo are registered trademarks or trademarks of
Alpine Immune Sciences, Inc. in various jurisdictions. All other
trademarks belong to their respective owners.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171023005346/en/
Source: Alpine Immune Sciences, Inc.
Alpine Immune Sciences, Inc.
Courtney Dugan, 212-257-6723
Jennifer Paganelli, 347-658-8290